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NF-kB is involved in a variety of biological processes, including cancer development. In this issue of Cancer
Cell, Kuo et al. show the essential role for IKK/NF-kB signaling in epigenetic regulation by MLL oncoproteins
to maintain leukemia stem cells.MLL fusion leukemia is an aggressive
blood cancer carrying chimeric fusion of
the MLL gene. The MLL gene encodes
a DNA-binding protein that contains a
C-terminal SET domain with histone H3
lysine 4 (H3K4) methyltransferase activity.
MLL is targeted by at least 70 different
chromosomal translocations, resulting in
the fusion of the 50 portion of MLL to a
number of different partner genes in leu-
kemia patients. MLL fusion proteins lose
the SET domain and H3K4 methyltrans-
ferase activity, but instead acquire aber-
rant functions for epigenetic regulation.
The H3K79-specific methyltransferase
DOT1L is associated with many of the
fusion partner proteins and enhances
H3K79 dimethylation at MLL fusion loci.
Wild-type MLL also collaborates with
MLL fusion proteins in regulating target
gene expression partly by increasing
H3K4 trimethylation. As a result, MLL
fusion proteins induce constitutive
expression of MLL target genes, including
HOXA9 and MEIS1, thereby promoting
self-renewal capabilities in hematopoi-
etic stem and progenitor cells. Recent
studies have identified several crucial
epigenetic regulators and chromatin
modifiers in MLL fusion leukemia. Those
include epigenetic modifying enzymes
DOT1L and PRMT1, histone demethy-
lase KDM1A, polycomb group proteins
EZH2 and CBX8, the PAFc complex, and
bromodomain-containing protein BRD4.
Inhibition of these factors has shown a
dramatic effect to reverse the inappro-
priate expression of keyMLL target genes
that drive leukemogenesis. Therefore,
therapeutic potential of targeting these
epigenetic regulators in MLL fusion leuke-
mia has received much attention in recent
years (Neff and Armstrong, 2013).In this issue of Cancer Cell, Kuo et al.
describe an unexpected role of IKK/NF-
kB signaling as a coordinator for epige-
netic regulation induced by MLL-fusion
proteins (Kuo et al., 2013). NF-kB is
a dimeric complex of transcription fac-
tors mainly consisting of RELA (p65)/p50
(NFKB1; canonical pathway) or RELB/
p52 (NFKB2; noncanonical pathway).
The canonical pathway broadly modu-
lates cell proliferation, survival, and
inflammation, whereas the noncanonical
pathway mainly controls lymphomagene-
sis. In the canonical pathway, the RELA/
p50 complex is held in the cytoplasm by
the inhibitory IkB. During activation,
IKKa/b/g complex phosphorylates IkB
and triggers its degradation, resulting in
nuclear translocation of RELA/p50 and
transactivation of target genes (Hayden
and Ghosh, 2008). By employing a non-
biased screening approach with a short
hairpin RNA (shRNA) library, the authors
found knockdown of multiple kinases/
phosphatases involved in NF-kB signaling
had substantial growth-inhibitory effects
in MLL fusion leukemia. Network ana-
lyses using global DNA methylation and
gene expression profiles in human acute
myeloid leukemia (AML) also revealed
the connection between NF-kB signaling
and MLL fusion leukemia. Furthermore,
NF-kBwas strongly activated by lipopoly-
sacccharide stimulation in MLL fusion
leukemia cells compared with other types
of leukemia cells. The authors then per-
formed extensive functional studies using
shRNAs, knockout mice, and pharmaco-
logical inhibitors for IKK/NF-kB signaling.
IKK inhibitors and RELA knockdown in-
hibited the growth of humanAML cell lines
with MLL fusion. In murine transformation
models, IKK inhibitors and shRNA-medi-Cancer Cell 24ated knockdown of key NF-kB molecules
(Ikka, Ikkb, Ikkg, and RELA) impaired
colony formation and in vivo leukemia
development induced by MLL fusion pro-
teins. Furthermore, cells derived from
RELA-deficient mice were unable to sus-
tain continuous replating of MLL-fusion-
transduced cells, confirming a functional
requirement for IKK/NF-kB signaling in
MLL leukemogenesis. Conversely, forced
RELA expression accelerated the devel-
opment of MLL fusion leukemia. Mecha-
nistically, IKK inhibitor treatment induced
cell-cycle arrest, apoptosis, differentia-
tion, and substantial reduction of leukemia
stem cell frequency in both mouse and
human MLL fusion leukemia cells. Gene
expression analysis suggested that
NF-kB is responsible for promoting the
oncogenic program associated with MLL
fusion leukemia. IKK inhibitors and RELA
knockdown decreased expression of the
primary MLL target genes Hoxa9 and
Meis1. Promoter occupancy profile of
RELA was similar to that of MLL-AF10,
and occupancy of both was reduced by
treatment with IKK inhibitors. Of note,
IKK inhibition also led to a decrease in
the epigenetic marks on the promoters of
Hoxa9 and Meis1 genes. IKK inhibitors
reduced promoter occupancy of MLL-
AF10, resulting in a loss of DOT1L-medi-
ated H3K79 dimethylation marks. Inhi-
bition of IKK also reduced binding of
wild-typeMLLand the level ofH3K4 trime-
thylation on Meis1 and Hoxa9 promoter
regions. Together, these results suggest
that IKK/NF-kB signaling is necessary
for maintaining epigenetic marks induced
by MLL fusion protein and wild-type MLL
in leukemia cells (Figure 1).
These exciting findings by Kuo et al. will
be the basis for much future basic and, October 14, 2013 ª2013 Elsevier Inc. 401
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Figure 1. Therapeutic Targeting of Canonical NF-kB Pathway in MLL-Fusion Leukemia
Inhibition of IKK/NF-kB signaling results in loss of epigenetic marks on HOXA9 and MEIS1 promoters,
which ultimately induces cell-cycle arrest, apoptosis, and differentiation in MLL fusion leukemia cells.
me3, trimethylation; me2, dimethylation. The figure is modeled on the online graphical abstract in Kuo
et al. (2013), with some modifications.
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Previewspreclinical research. Many studies have
focused on downstream signals associ-
ated with oncogene expression in an
attempt to reveal the addictive signals
that can be therapeutically targeted
in cells expressing the oncogene. One
particularly novel outcome of this study is
the identificationof anupstreampre-exist-
ing signaling pathway that converges on
MLL and MLL fusion protein recruitment
to chromatin. BlockadeofNF-kBsignaling
could be expected to interfere with all
signals emanating fromMLL fusion activa-
tion of HoxA9 andMeis1 expression. How
broadly NF-kB regulation impacts onMLL
and MLL fusion signaling and whether
NF-kB plays a role in regulating other
MLL target genes, such as MECOM/
Evi1 (Arai et al., 2011), remain to be
determined. The particular association
between NF-kB and MLL fusion leukemia
raises additional questions that warrant
further study. Numerous other subclasses
of AML show increased HoxA9 andMeis1
expression, including the NPM1c-associ-
ated subtype, but no overlapping gene
sets were identified that would implicate
NF-kB in HoxA9 regulation in this AML
subset. How these genes are regulated
independently of NF-kB signals could
reveal novel signaling cascades that
can be therapeutically targeted in these402 Cancer Cell 24, October 14, 2013 ª2013AMLs. Whether NF-kB is also required
for MLL-partial tandem duplication medi-
ated leukemia is of interest, as this genetic
aberration is recognized as a frequent
player in myelodysplastic syndrome and
AML. In addition, the data from this study
raise questions as to whether NF-kB
signaling works collaboratively with other
epigenetic regulators in various biological
processes. Interestingly, recent studies
have shown that wild-type MLL stabi-
lizes RUNX1 (Huang et al., 2011), that
RUNX1 attenuates NF-kB signaling
through interaction with IKK complex
(Nakagawa et al., 2011), and that deletion
of Runx1 could accelerate MLL-ENL
mediated AML in a mouse model (Nishi-
moto et al., 2011). Therefore, it is tempting
to speculate that reduced RUNX1 expres-
sion may be required in MLL fusion leuke-
mia for full NF-kB activation. We can also
not ignore NF-kB functions independent
of epigenetic regulation in MLL fusion
leukemia. Crosstalk between NF-kB and
other signaling pathways that are known
to be active in MLL fusion leukemia,
such as WNT (Wang et al., 2010) and Rac
(Mizukawa et al., 2011; Wei et al., 2008),
may play important roles in promoting
leukemogenesis.
Although there are several unanswered
mechanistic questions, the results pre-Elsevier Inc.sented in this article highlight the potential
therapeutic implications of targeting IKK/
NF-kB signaling in MLL fusion leukemia.
Targeting this pathway may also be effec-
tive in other types of AML. For example,
Nakagawa et al. recently showed that
inhibition of NF-kB signaling efficiently
blocked the growth of RUNX1-mutated
leukemia cells (Nakagawa et al., 2011).
Moreover, such therapies will perhaps
have promise for treating other types of
cancer that are dependent on similar
aberrant transcriptional or epigenetic ac-
tivity for survival. Given the diverse func-
tions of NF-kB, however, side effects of
NF-kB-directed therapy will be a concern.
Indeed, Kuo et al. pretreated leukemia
cells prior to transplantation for the in vivo
study in this article, because IKK inhibi-
tors used in their study were too toxic for
chronic systemic administration to mice.
Careful in vivo preclinical studies, ideally
with primary AML cells and various inhib-
itors for the IKK/NF-kB signaling pathway,
will be necessary before translating these
findings into the clinic.
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